DUXAP8 and renal cell carcinoma: Chen et al. (2019) demonstrated that DUXAP8 and DUXAP9 were significantly upregulated in renal cell carcinoma, promoted tumor growth and served as two unfavorable prognostic biomarkers for patients with renal cell carcinoma.